According to a survey of 53 China-focused life science investors, 79% of the respondents believe the US is the current global leader in innovation for life science while only 15% picked China. But fast forward six years to expectations for 2025, the ...

ChinaBio® Daily Update

Contents


Investor Survey: US Leads Global Healthcare Innovation, but China to Catch Up by 2025

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

According to a survey of 53 China-focused life science investors, 79% of the respondents believe the US is the current global leader in innovation for life science while only 15% picked China. But fast forward six years to expectations for 2025, the vote was split evenly between the two countries at about 48% each, a big turnaround. The data comes from an online survey conducted by Healthcare Drinks, an industry networking group that presented the survey results at its most recent event, which was held at the Harvard Business School Club of Shanghai earlier this month. More details....

     
 

AllinMD Closes $100 Million Series B for Online/Hospital Orthopedic Services

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

AllinMD Orthopedics Hospital of Beijing closed a $100 million Series B round to build its combination of orthopedic hospitals and internet medical care. The round was led by Sheares, a medical care fund of Singapore's sovereign wealth fund Temasek, and H Capital, a US venture capital firm. Tencent and Trustbridge Partners also participated. AllinMD will use the capital to increase the number of its physical hospitals while also expanding its online education services to more orthopedic doctors in China’s smaller cities and rural areas. More details....

Share this with colleagues:

     
 

Chipscreen's NDA for Novel Type 2 Diabetes Drug Accepted for China Review

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shenzhen Chipscreen Biosciences reported its new drug application for a first-in-class type 2 diabetes treatment was accepted for review in China. Chiglitazar, a novel small molecule peroxisome proliferator-activated receptor (PPAR) α/γ/δ pan-agonist, acts as an insulin sensitizer. The first PPAR pan-agonist to complete Phase III clinical trials, chiglitazar showed durable efficacy in glycemic control for patients with T2DM and metabolic syndrome. In August, Chipscreen completed a $147 million IPO on the Shanghai STAR board and rose 367% in its first trading day. More details....

Stock Symbol: (SHA: 688321)

Share this with colleagues:

     
 

China Biologic Products Receives $4.6 Billion Takeover Offer

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

China Biologic Products, a blood products company, received a $4.6 billion takeover offer from a group of six investment firms. The proposal was priced at $120 per share, a 16% premium to the previous close. CBPO operates plasma-gathering facilities (China limits the number of such facilities) and offers 20 plasma-based products. The company is priced at about 30 times trailing earnings. One year ago, CITIC made a $3.9 billion offer for CBPO, which was topped by a syndicate led by a former CEO of the company. CBPO rejected both bids. More details....

Stock Symbol: (NSDQ: CBPO)

Share this with colleagues:

     
 

Henlius Prices Hong Kong IPO at the Bottom of the Range, Raising $410 Million

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.

Shanghai Henlius Pharma raised $410 million in its Hong Kong IPO at a market cap of $2.9 billion, the low end of the range. The company is the majority-owned biologics subsidiary of Fosun Pharma. At the top end of the range, Henlius would have raised $477 million in its debut offering. Fosun and Henlius, a US company, formed the China biologics JV in 2010. In February, the company was approved for a China launch of a biosimilar to Roche's Rituxan, a lymphoma treatment. More details....

Stock Symbols: (HK: 2696) (SHA: 600196; HK: 2196)

Share this with colleagues:

     
 

More Recent Articles

Written by Richard Daverman, PhD, Executive Editor, Greg B. Scott.


Not a ChinaBio®Today Subscriber?

Here's what you get with a paid subscription to ChinaBio® Today:
  • Website access to all current articles and commentary
  • Full access to over 2000 archived articles on the biotech industry

Greg B. Scott
Executive Editor
ChinaBio® Today


ChinaBio and ChinaBio Today are trademarks of ChinaBio LLC


 


Safely Unsubscribe ArchivesPreferencesContactSubscribePrivacy